STEMCELL Technologies, Canada’s largest biotechnology company, has received the Canada’s Most Admired Corporate Cultures™ of 2023 award by Waterstone Human Capital. This national awards program recognizes best-in-class Canadian organizations for fostering…
Hologic, Inc. (Nasdaq: HOLX) will showcase several recent developments in next-generation AI solutions at the 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov.…
Natura Bissé and Arch Amenities Group Europe today announce a collaboration agreement with the aim of increasing their presence in the luxury spa sector throughout the European Union and the…
The University of Wisconsin School of Medicine and Public Health at UW–Madison and GE HealthCare announced today a 10-year strategic collaboration that builds on an iconic relationship spanning more than…
Cofactor Genomics, the company bridging the precision medicine gap, today announced successful validation of the OncoPrism immunotherapy predictive diagnostic assay, enabling physicians to use the test to help guide treatment…
BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today announced the presentation of encouraging data from its Phase 2…
Genome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference Genome Insight, a precision healthcare solutions company advancing whole-genome technology for…
Paragon 28 Adds Second Mobile Medical Education Lab Significantly Expanding Upon Wildly Successful Foot and Ankle Surgeon Training Program Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition…
Vicarious Surgical Reports Third Quarter 2023 Financial Results Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes…
Oak Street Health, a network of value-based primary care centers for adults on Medicare and the only primary care provider to carry the AARP name, is now welcoming patients at the…
Novartis today announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib – a highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor – in people with…
Beginning Jan. 1, 2024, Optum Rx will place eight preferred insulin products on tier one of standard commercial formularies, limiting out-of-pocket spend to $35 or less. Optum Rx, a pharmacy…